The global women’s health market was valued at USD 51.24 Billion in 2024, driven by the increasing awareness and focus on women-specific diseases and the growing adoption of advanced diagnostic and therapeutic technologies across the globe. The market is anticipated to grow at a CAGR of 5.20% during the forecast period of 2025-2034, with the values likely to reach USD 85.07 Billion by 2034. The market growth is driven by expanding healthcare infrastructure and increasing investments in women’s health research. The rising demand for personalized treatments and advancements in digital health solutions further contribute to market growth during the forecast period.
Organon & Co.
Established in 1923 with headquarters in Jersey City, New Jersey, Organon is a global healthcare company dedicated to women’s health. In 2024, it entered a licensing agreement with Bao Pharmaceutical to commercialize SJ02, an innovative long-acting follicle-stimulating hormone for assisted reproductive technology in China. This advances Organon’s commitment to expanding fertility treatment options worldwide.
Other key players in the market include Bayer AG, Agile Therapeutics, Amgen, Inc., Apothecus Pharmaceutical Corp., Blairex Laboratories, Inc., and Ferring.
This product will be delivered within 3-5 business days.
Global Women’s Health Market Overview
Women’s health focuses on the diagnosis, treatment, and prevention of conditions unique to females, including reproductive, hormonal, and gynecological health, as well as general wellness across different life stages. The market is driven by rising awareness, increasing healthcare access, and advancements in medical technologies. It encompasses a broad range of services, products, and therapies addressing female-specific needs, from fertility to menopause. The market is poised to grow at a CAGR of 5.20% during the forecast period of 2025-2034, supported by ongoing research, favorable government initiatives, and a growing emphasis on personalized and preventive healthcare for women.Global Women’s Health Market Growth Drivers
Innovative Global Initiatives to Accelerate the Growth in the Market
The increasing implementation of global health initiatives targeting underserved populations is a major driver of growth in the women’s health market. For example, in October 2024, UNFPA launched the WomenX Collective during the World Health Summit in Berlin. This groundbreaking initiative aims to improve reproductive and maternal health in low- and middle-income countries by establishing innovation hubs, beginning in Berlin and expanding to Nairobi by 2025. With a USD 100 million investment goal by 2030 and support from key international donors, the initiative is expected to strengthen access to healthcare and significantly boost the women’s health market worldwide.Women’s Health Market Trends
The market is experiencing several key trends, including an increasing global focus on women’s health and growing investment in the sector.Rising Global Focus on Women’s Health Fuels Market Expansion
There is a heightened emphasis on women’s nutrition and preventive healthcare, particularly in underserved regions. In March 2024, the WTA Foundation and Bill & Melinda Gates Foundation launched the groundbreaking “Women Change the Game” campaign, which aims to provide prenatal vitamins to over one million women in low- and middle-income countries during its first year. This initiative brings critical attention to persistent health disparities and unmet needs, stimulating innovation, funding, and broader access to essential women’s health products. Consequently, this growing focus is expected to significantly boost market growth and value in the coming years.Increasing Investment in Women’s Health to Fuel Women’s Health Market Demand
Increasing global investment in women’s health is a key trend shaping the market. For example, in October 2024, Pivotal Philanthropies Foundation announced a USD 250 million global open call to fund organizations improving women’s mental and physical health, supporting Melinda French Gates’s broader USD 1 billion commitment. This surge in funding is expected to drive innovation and significantly enhance growth prospects within the market.Women’s Health Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
- Hormonal Therapies
- Bone Health Agents
- Fertility Agents
- Pain and Symptom Management
- Others
Market Breakup by Application
- Hormonal Infertility
- Contraceptives
- Postmenopausal Osteoporosis
- Polycystic Ovary Syndrome (PCOS)
- Menopause
- Others
Market Breakup by Age Group
- Below 40 years
- 40 to 50 Years
- Above 50 years
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Women’s Health Market Share
Fertility Agents to Lead the Segmentation by Drug Class
Reproductive health and contraception are projected to lead the global women’s health market, significantly shaping its growth trajectory. Increasing adoption of modern contraceptives has enhanced preventive care, reduced healthcare costs, and improved maternal and child health outcomes. According to 2024 Family Planning data, 380 million women and girls in low- and lower-middle-income countries now use modern contraception, helping prevent 143 million unintended pregnancies, 144,000 maternal deaths, and 29 million unsafe abortions from July 2023 to July 2024. This surge underscores growing investment and innovation in reproductive health. Other key segments include menopause, osteoporosis, cancer, urology, and others.Women’s Health Market Analysis by Region
The market report covers several regions including North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Among these, North America is anticipated to maintain a leading position due to its advanced healthcare infrastructure, high patient awareness, supportive regulatory environment, and rapid adoption of innovative medical technologies. For example, in 2024, ConTIPI Medical, in partnership with Eversana, successfully launched ProVate in the United States. This disposable, non-surgical device addresses pelvic organ prolapse and offers women a convenient, at-home treatment option, reflecting the region’s emphasis on patient-centered care and technological advancement.Leading Players in the Global Women’s Health Market
The key features of the market report comprise patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:AbbVie, Inc
AbbVie, Inc., headquartered in North Chicago, Illinois, was established in 2013. Through its Allergan Aesthetics division, AbbVie offers advanced products in women's health, including facial injectables and skin care treatments. In 2024, AbbVie, along with SkinSpirit, a leading medical aesthetics provider founded in 2002, strengthened their market presence by supporting women’s empowerment initiatives, reflecting their commitment to innovation and leadership in women’s health.Organon & Co.
Established in 1923 with headquarters in Jersey City, New Jersey, Organon is a global healthcare company dedicated to women’s health. In 2024, it entered a licensing agreement with Bao Pharmaceutical to commercialize SJ02, an innovative long-acting follicle-stimulating hormone for assisted reproductive technology in China. This advances Organon’s commitment to expanding fertility treatment options worldwide.
Pfizer, Inc
Pfizer, Inc., headquartered in New York City and established in 1850, plays a significant role in the global women’s health market through impactful initiatives. In January 2025, the Pfizer Foundation committed USD 15 million to improve breast cancer care in Sub-Saharan Africa. This investment supports programs focused on early diagnosis, accelerating treatment access, and overcoming healthcare barriers, reflecting Pfizer’s strong dedication to advancing women’s health and promoting global health equity.Theramex
Headquartered in London, United Kingdom, Theramex is a leading global pharmaceutical company dedicated exclusively to women’s health. In December 2024, the European Commission approved an extended indication for its oral gonadotropin-releasing hormone (GnRH) antagonist, Yselty (linzagolix), to treat symptomatic endometriosis in adult women with a history of previous medical or surgical treatment. This approval reinforces Theramex’s commitment to developing innovative and effective therapies across key areas such as contraception, fertility, menopause, and osteoporosis, aiming to improve the quality of life for women worldwide.Other key players in the market include Bayer AG, Agile Therapeutics, Amgen, Inc., Apothecus Pharmaceutical Corp., Blairex Laboratories, Inc., and Ferring.
Key Questions Answered in the Global Women’s Health Market Report
- What was the global women’s health market value in 2024?
- What is the global women’s health market forecast outlook for 2025-2034?
- What are the major factors aiding the global women’s health market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major global women’s health market trends?
- Which drug class is expected to dominate the market segment?
- Which application is anticipated to drive the market segment?
- Which age group is likely to dominate the market segment?
- Who are the key players involved in the global women’s health market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Global Women’s Health Market Overview
4 Vendor Positioning Analysis
5 Global Women’s Health Market Landscape
6 Global Women’s Health Market Dynamics
7 Global Women’s Health Market Segmentation (218-2034)
8 North America Women’s Health Market (218-2034)
9 Europe Women’s Health Market (218-2034)
10 Asia Pacific Women’s Health Market (218-2034)
11 Latin America Women’s Health Market (218-2034)
12 Middle East and Africa Women’s Health Market (218-2034)
13 Regulatory Framework
14 Patent Analysis
15 Grants Analysis
16 Funding and Investment Analysis
17 Strategic Initiatives
18 Supplier Landscape
19 Global Women’s Health Market - Distribution Model (Additional Insight)
Companies Mentioned
- AbbVie, Inc.
- Organon & Co.
- Pfizer, Inc.
- Theramex
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 400 |
Published | June 2025 |
Forecast Period | 2025 - 2034 |
Estimated Market Value ( USD | $ 51.24 Billion |
Forecasted Market Value ( USD | $ 85.07 Billion |
Compound Annual Growth Rate | 5.2% |
Regions Covered | Global |
No. of Companies Mentioned | 4 |